Laura Alder, Thoracic Medical Oncologist at Duke University School of Medicine, shared on X:
“Who’s ready for SCLC updates at WCLC26?!
Dr Jonathan Goldman presents DeLLphi-309: randomized Phase 2 of tarlatamab extended-interval dosing in SCLC.
Less-frequent dosing could ease treatment burden and ‘time toxicity,’ keeping efficacy while giving patients back more days off therapy.
Dr Alberto Chiappori on LB2102: a dnTGFBR2-armored, DLL3-targeted autologous CAR-T in relapsed/refractory SCLC and LCNEC.
Brings the promise of durable, one-time cell therapy, and the hope of long-term benefit to a disease that relapses fast.
Dr Zhuxing Xia reveals how epigenetic dysregulation drives E2F1-mediated neuroendocrine transformation in EGFR-mutant lung adenocarcinoma.
Transformed patients face a poor prognosis with few options, this mechanistic insight addresses a critical unmet need and points toward new targets.
Discussant: Dr Hiroaki Akamatsu – Q&A 5:27 – 6:00 PM
Session OA05 ‘From Discovery to Practice in SCLC’ – Sunday Sept 13, 4:45 PM KST, Room 103.”
Other articles about WCLC26 on OncoDaily.
